Table 4.
Multivariate analysis of drug burden index scores and potential adverse effects (n = 484)a
| DBI 0 > 1 | DBI ≥ 1 | |||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Daytime dozing | ||||
| No | 1 (reference) | 1 (reference) | ||
| Yes | 1.108 (0.568;2.162) | 0.764 | 1.670 (0.916;3.044) | 0.094 |
| Chronic constipation | ||||
| No | 1 (reference) | 1 (reference) | ||
| Yes | 1.276 (0.643;2.532) | 0.486 | 1.679 (0.902;3.123) | 0.102 |
| Fall in the previous 12 months | ||||
| No | 1 (reference) | 1 (reference) | ||
| Yes | 0.611 (0.303;1.231) | 0.168 | 1.113 (0.605;2.046) | 0.731 |
a
Reference category: DBI 0. P < 0.05 is significant, all significant factors in bold. Cox and Snell r2 = 0.245, Nagelkerke r2 = 0.284. Data are adjusted odds ratio (OR) with 95% confidence interval (CI). Model adjusted for sex, age, level of intellectual disabilities, type of residence, behaviours that challenge, comorbidities (functional comorbidity index) and number of non‐drug burden index medicines.